Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
Approval of the parent company financial statements and consolidated financial statements for the 2022 financial year
Distribution of a cash dividend of 3.56 euros per share, payment of which will take place on 1
er
June 2023Composition of the Board of Directors: Frédéric Oudéa is appointed independent director and Chairman of the Board of Directors
Paris, May 25, 2023
. The Combined General Meeting of Sanofi shareholders met on May 25, 2023, under the chairmanship of Serge Weinberg.
The Meeting notably approved the parent company and consolidated financial statements for the 2022 financial year. The Meeting decided to distribute an ordinary annual dividend of 3.56 euros per share. The payment of the dividend will take place on 1
er
June 2023.
The Meeting also approved the appointment of Frédéric Oudéa as independent director. The Board of Directors, in its meeting held after the general meeting, appointed Frédéric Oudéa as Chairman of the Board of Directors to succeed Serge Weinberg, whose term of office expired at the end of the Assembly. Serge Weinberg has been appointed Honorary Chairman.
On the proposal of the Appointments, Governance and CSR Committee, Frédéric Oudéa was appointed Chairman of the Strategic Reflection Committee, member of the Appointments, Governance and CSR Committee and of the Scientific Committee.
Frederic Oudea
President of Sanofi
“ I am very pleased to join the Board of Directors and I feel privileged to assume the role of Chairman. I would like to express Sanofi’s appreciation to Serge Weinberg for his outstanding leadership during his thirteen years as Chairman, leading the Company to historically high value and transformative momentum through his leadership in immunology and inflammation. He carried out his mission with integrity and commitment, in the interest of the company. I thank the shareholders and the Board of Directors for their confidence. I am extremely motivated by the prospects for scientific progress and growth that Sanofi has the potential to achieve, as well as by its vocation to pursue the miracles of science to improve people’s lives. I look forward to contributing to the growth and sustainable development of Sanofi in accordance with the highest standards of corporate governance. ”
At the end of this Meeting, the Board of Directors remains composed of 16 directors, including six women and two directors representing the employees. The Board’s independent rate increased from 71% to 79%.
Find the results of the votes and the broadcast of the General Assembly here.
About Sanofi
We are an innovative, global health company driven by one purpose: to pursue the miracles of science to improve people’s lives. Our teams, present in a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media relations
Sandrine Guendoul
| + 33 6 25 09 14 25 |
Nicholas Obrist
| + 33 6 77 21 27 55 |
Victor Rouault
| + 33 6 70 93 71 40 |
Investor Relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud Delépine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| + 1 908 612 7239 | [email protected]
Tarik Elgoutni |
+ 1 617 710 3587 | [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected]
Attachment